sumatriptan intranasal / Generic mfg. - LARVOL DELTA

Drug interventions for acute treatment of pediatric migraine: a systematic review and network meta-analysis. (PubMed, Front Pharmacol) - "Sumatriptan/naproxen sodium, ibuprofen, zolmitriptan nasal spray, sumatriptan nasal spray, and rizatriptan showed statistical significance. Sumatriptan/naproxen sodium merits consideration, especially in patients exhibiting an inadequate response to monotherapy. Dihydroergotamine demonstrated potential benefits in refractory and chronic migraine; however, high-quality studies are warranted to validate these findings."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain • Pediatrics

Comparison of FDA approved intranasal acute migraine treatment adverse event profiles (AHS 2026) - "One Sentence Summary: STS101 (dihydroergotamine nasal powder) shows a low rate of local adverse events in its approved prescribing information as compared with other approved intranasal acute migraine treatments...Prescribing information dates reviewed were ATZUMI (April 2025), Migranal (September 2022), Trudhesa (May 2022), Zavzpret (August 2025), Imitrex nasal spray (December 2025), and Zomig nasal spray (May 2019)... Nasally administered products for the acute treatment of migraine are generally well tolerated. STS101 shows a favorable adverse event profile in long term prn use as compared with other FDA-approved intranasal acute migraine treatments. Most commonly reported adverse events (≥5% and occurring more frequently than placebo) as listed in the U.S. prescribing information for FDA-approved intranasal acute migraine treatments."

Adverse events • CNS Disorders • Migraine • Pain

Rimegepant as an acute therapy for cluster headache: A case report (AHS 2026) - "One Sentence Summary: This case describes a 47-year-old male with episodic cluster headache on galcanezumab whose acute attacks are successfully resolved with rimegepant...Sumatriptan nasal spray provided incomplete relief... This case highlights the potential efficacy of rimegepant as an acute treatment for cluster headache. Rimegepant was associated with a rapid and sustained response with excellent tolerability. Further investigation is warranted to evaluate the treatment of cluster headache attacks with rimegepant."

Case report • Clinical • CNS Disorders • Migraine • Pain

The Role of Nasal Drug Delivery in Migraine Management and Brain-Targeted Therapy: Insights From Taiwan. (PubMed, Biopharm Drug Dispos) - "Drawing on first hand experiences as a psychiatrist and migraine patient in Taiwan, the response discusses the practical benefits and challenges of using nasal formulations, such as sumatriptan nasal spray, during ongoing drug shortages...The letter highlights the potential of advanced technologies like nanocarriers to improve nasal drug delivery and emphasizes the need for patient-centered designs. The correspondence concludes with recommendations for diversifying drug delivery approaches to enhance efficacy and accessibility."

Journal • CNS Disorders • Migraine • Pain • Psychiatry

Tonix Pharmaceuticals Announces Commitment to Supply Tosymra (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSK’s Planned Discontinuation of Imitrex (sumatriptan) Nasal Spray After January 2024 (GlobeNewswire) - "Tonix Pharmaceuticals Holding Corp...announced that it is committed to meeting potential increased demand for Tosymra^® (sumatriptan) nasal spray 10 mg after GlaxoSmithKline’s (GSK) planned discontinuation of Imitrex (sumatriptan) nasal spray 5 mg and 20 mg products after January, 2024....On August 8, 2023, GSK informed the U.S. Food and Drug Administration (FDA) of its plan to discontinue Imitrex nasal spray 5 mg and 20 mg doses after January 31, 2024....Tonix is preparing for potential increased demand for Tosymra (sumatriptan nasal spray) 10 mg to help avoid possible drug shortages for patients who suffer from migraines. Tosymra nasal spray is approved on the basis of bioequivalence to Imitrex injection 4 mg."

Commercial • Discontinued • CNS Disorders • Migraine • Pain

Feasibility, Utility, and Interrater Reliability of the Cluster Headache Severity Scale, Cluster Headache Quality of Life, Cluster Headache Index, and 6-Item Headache Impact Test in Pediatric Cluster Headache. (PubMed, J Child Neurol) - "All children responded to prednisolone as bridging therapy and 23 of 32 showed adequate pain relief after sumatriptan nasal spray for an acute attack... Majority of pediatric cluster headache patients are likely to respond to prednisolone and sumatriptan. Cluster Headache Severity Scale, Cluster Headache Quality of Life, and Headache Impact Test-6 can be used for pediatric cluster headache patients for treatment monitoring."

HEOR • Journal • Pain • Pediatrics

Drugs for Acute Attack of Pediatric Migraine: A Network Meta-analysis of Randomized Controlled Trials. (PubMed, Clin Neurol Neurosurg) - "We found that sumatriptan nasal spray and zolmitriptan nasal spray were superior to placebo in the two efficacy outcomes, whereas almotriptan, rizatriptan, sumatriptan with naproxen sodium, ibuprofen and ibuprofen suspension were superior to placebo only in one of the efficacy outcomes. And the most effective treatment to achieve pain-free is sumatriptan with naproxen sodium. Ibuprofen and ibuprofen suspension were the most effective treatments to achieve pain-relief."

Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain • Pediatrics

Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics. (PubMed, Eur J Clin Pharmacol) - "This study evaluated the efficacy characteristics of seven kinds of triptans and their different dosage forms. The present findings provide necessary quantitative information for migraine medication guidelines."

Clinical • Journal

Development and evaluation of in-situ nasal gel formulations of nanosized transferosomal sumatriptan: Design, optimization, in vitro and in vivo evaluation (Dovepress) - "Pharmacokinetic evaluation showed that the prepared in-situ gel of SUT [Sumatriptan succinate]-loaded nano-transferosomes gave enhanced bioavailability, 4.09-fold, as compared to oral drug solution.... Based on enhancing the bioavailability and sustaining the drug release, it can be concluded that the in-situ gel of SUT-loaded nano-transferosomes were developed as a promising non-invasive drug delivery system for treating migraine."

Clinical data

Therapeutic Effects of Intranasal Sumatriptan for Cluster Headache (PubMed, Yakugaku Zasshi) - "Oxygen inhalation and/or subcutaneous injection were effective for nonresponsive cases. Therefore, these factors are considered to be useful for predicting therapy before applying sumatriptan nasal spray."

Journal